Teva Pharmaceutical Industries Ltd (TEVA)

29.42
0.46 1.50
NYSE : Health Care
Prev Close 29.88
Open 29.93
Day Low/High 29.36 / 30.06
52 Wk Low/High 29.46 / 56.44
Volume 6.16M
Avg Volume 6.96M
Exchange NYSE
Shares Outstanding 1.02B
Market Cap 30.14B
EPS 0.10
P/E Ratio 5.77
Div & Yield 1.36 (4.60%)

Latest News

Teva To Present Data For Deutetrabenazine In Tardive Dyskinesia At The American Psychiatric Association 2017 Annual Meeting

Teva To Present Data For Deutetrabenazine In Tardive Dyskinesia At The American Psychiatric Association 2017 Annual Meeting

Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced eight abstracts evaluating deutetrabenazine tablets - formerly referred to as SD-809 - for the treatment of tardive dyskinesia (TD) will be...

Teva Announces Launch Of Generic Glumetza® In The United States

Teva Announces Launch Of Generic Glumetza® In The United States

Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced the launch of generic Glumetza ®1 (metformin hydrochloride extended-release tablets), 500 mg and 1000 mg, in the U.

Otsuka And Teva Sign Licensing Agreement For Japan On Prophylactic Migraine Drug Candidate Fremanezumab (TEV-48125)

Otsuka And Teva Sign Licensing Agreement For Japan On Prophylactic Migraine Drug Candidate Fremanezumab (TEV-48125)

Otsuka Pharmaceutical Co., Ltd (Otsuka) and Teva Pharmaceutical Industries, Ltd.

Merck Up on Approval, Teva Sinks on Earnings and Asset Sales: Biotech Movers

Merck Up on Approval, Teva Sinks on Earnings and Asset Sales: Biotech Movers

The approval marks the first time that an immunotherapy has been combined with another drug to kill cancer cells more effectively.

Teva Reports First Quarter 2017 Financial Results

Teva Reports First Quarter 2017 Financial Results

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA, TASE: TEVA) today reported results for the quarter ended March 31, 2017.

Teva And Active Biotech Announce CONCERTO Trial Of Laquinimod In RRMS Did Not Meet Primary Endpoint

Teva And Active Biotech Announce CONCERTO Trial Of Laquinimod In RRMS Did Not Meet Primary Endpoint

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and Active Biotech (NASDAQ OMX NORDIC: ACTI) today announced results from the CONCERTO trial in patients with relapsing-remitting multiple sclerosis (RRMS).

Teva Announces Publication Of COPAXONE® (glatiramer Acetate Injection) Pregnancy Data In The International Journal Of MS Care

Teva Announces Publication Of COPAXONE® (glatiramer Acetate Injection) Pregnancy Data In The International Journal Of MS Care

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that data suggests that women with relapsing forms of multiple sclerosis (RMS) who were exposed to COPAXONE ® 20 mg/mL daily during pregnancy...

Generics Drop Across Board as DOJ Inquiry Expands

Generics Drop Across Board as DOJ Inquiry Expands

The addition of Perrigo to the list of generics makers under investigation is more bad news for a sector already under pressure from low prices.

Perrigo Stock Sliding on DOJ Search

Perrigo Stock Sliding on DOJ Search

The investigation is in relation to drug pricing in the pharmaceutical industry.

Teva Pharmaceutical Is Ready for a Tradable Rally

Teva Pharmaceutical Is Ready for a Tradable Rally

Prices are extended on the downside.

Teva Announces Publication Of ARM-TD Study Results In Neurology® For The Investigational Use Of Deutetrabenazine In Tardive Dyskinesia

Teva Announces Publication Of ARM-TD Study Results In Neurology® For The Investigational Use Of Deutetrabenazine In Tardive Dyskinesia

Teva Pharmaceutical Industries Ltd. (NYSE and TASE:TEVA) today announced the publication of results from the Phase II/III study ARM-TD ( A im to R educe M ovements in T ardive D yskinesia) in...

Teva Announces Launch Of Generic Vytorin® In The United States

Teva Announces Launch Of Generic Vytorin® In The United States

Teva Pharmaceutical Industries Ltd., (NYSE and TASE:TEVA) today announced the launch of generic Vytorin ®1 (ezetimibe and simvastatin) tablets in the U.

Teva Confirms CFO Is Leaving

Teva Confirms CFO Is Leaving

Eyal Desheh became the Israel-based drugmaker's CFO in 2008.

Teva Announces Planned Departure Of Eyal Desheh, Group Executive Vice President And Chief Financial Officer

Teva Announces Planned Departure Of Eyal Desheh, Group Executive Vice President And Chief Financial Officer

Teva Pharmaceutical Industries Ltd. (NYSE and TASE:TEVA) today confirmed that Eyal Desheh, Group Executive Vice President, Chief Financial Officer, will depart from Teva during the coming months.

Why Mylan, Perrigo and Endo Won't Be Playing Spoiler in Akorn-Fresenius Tie Up

Why Mylan, Perrigo and Endo Won't Be Playing Spoiler in Akorn-Fresenius Tie Up

Fresenius announced a deal to buy U.S. generic drugmaker Akorn Inc for $4.75 billion, or $34 per share.

Novartis, Amgen Divvy Global Marketing of New Migraine Drug

Novartis, Amgen Divvy Global Marketing of New Migraine Drug

Estimates for erenumab annual sales run as high as $2.3 billion.

Teva Pharmaceutical CFO Stepping Down

Teva Pharmaceutical CFO Stepping Down

It is being reported that Teva will lose its CFO.

EQT Midstream Partners, AbbVie, Blackstone Group: 'Mad Money' Lightning Round

EQT Midstream Partners, AbbVie, Blackstone Group: 'Mad Money' Lightning Round

Jim Cramer is bullish on EQT Midstream Partners, AbbVie, Blackstone Group, and Core Civic.

Here's Why You Should Hope for Panic: Cramer's 'Mad Money' Recap (Friday 4/21/17)

Here's Why You Should Hope for Panic: Cramer's 'Mad Money' Recap (Friday 4/21/17)

Jim Cramer looks at how the French elections are smacking the U.S stock markets. Plus, he has the week-ahead game plan for oil and stocks.

Teva Launches AirDuo™ RespiClick® And Its Authorized Generic, Two Inhalers Containing Fluticasone Propionate And Salmeterol

Teva Launches AirDuo™ RespiClick® And Its Authorized Generic, Two Inhalers Containing Fluticasone Propionate And Salmeterol

Teva Pharmaceutical Industries Ltd., (NYSE and TASE:TEVA) today announced the simultaneous launch of AirDuo ™ RespiClick ® (fluticasone propionate and salmeterol) inhalation powder and its authorized generic for...

Teva Showcases CNS Portfolio At 69th Annual Meeting Of The American Academy Of Neurology

Teva Showcases CNS Portfolio At 69th Annual Meeting Of The American Academy Of Neurology

Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced data for five of the Company's innovative therapies for central nervous system (CNS) disorders will be presented at the 69 th Annual Meeting of the...

We've Stepped Into Panicky Territory, but Don't Panic

We will be oversold enough to have a rally this coming week.

2 Biotech Pullback Targets

2 Biotech Pullback Targets

Acadia and Neurocrine both have catalysts for growth; buy any weakness.

Neurocrine Biosciences Snags U.S. Approval for Movement Disorder Drug

Neurocrine Biosciences Snags U.S. Approval for Movement Disorder Drug

The U.S. Food and Drug Administration granted Ingrezza a relatively clean label that does not include a black box safety warning against suicidality or depression.

Allergan and Celgene Are in Peak Health

Allergan and Celgene Are in Peak Health

These stocks should be part of a strong first-quarter earnings season.

Teva Pharmaceutical Said to Be Exploring Sale of Women's Health Unit

Teva Pharmaceutical Said to Be Exploring Sale of Women's Health Unit

Teva Pharmaceutical's women's health business could sell for $2 billion.

Teva To Report First Quarter 2017 Financial Results On May 11, 2017

Teva To Report First Quarter 2017 Financial Results On May 11, 2017

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced today that it will release its first quarter 2017 financial results on Thursday, May 11, 2017 at 7:00 a.

Mylan Has Been Pounded, but the Pain May be Far from Over

Mylan Has Been Pounded, but the Pain May be Far from Over

The maker of the EpiPen seems incapable of overcoming its troubles.